Background-Experimental studies suggest that arterial injury and inflammation lead to increased neointimal growth after stenting. Despite the increased use of coronary stents in humans, there are only limited pathological data on the morphological features of in-stent restenosis. Methods and Results-Detailed histology was performed on 116 stents, implanted Ն90 days in 87 coronary arteries, from 56 patients (mean age, 59Ϯ13 years). The mean duration of stent implant was 10 months. In-stent restenosis was defined as a stent area stenosis of Ͼ75%. Lumen area increased as stent area increased (r 2 ϭ0.27, Pϭ0.0001), but there was a much stronger correlation between stent area and neointimal area (r 2 ϭ0.70, PϽ0.0001). Arterial medial fracture was associated with a 29% increase (PϽ0.01) in neointimal thickness compared with arteries with an intact media. Neointimal thickness (Pϭ0.0001), inflammatory cell density (PϽ0.0001), and neointimal vascular channel density (PϽ0.0001) were greater when struts were in contact with a ruptured arterial media compared with fibrous plaque or an intact fibrous cap. Stent strut penetration into a lipid core was associated with increased neointimal thickness (Pϭ0.04) and inflammatory cell density (Pϭ0.03). Neointimal inflammatory cell content was 2.4-fold greater in stents with restenosis versus no restenosis, and inflammation was associated with increased neoangiogenesis. Conclusions-Coronary stenting that is accompanied by medial damage or penetration of the stent into a lipid core induces increased arterial inflammation, which is associated with increased neointimal growth. These data suggest the use of stenting strategies that reduce inflammation and neoangiogenesis to reduce the incidence of restenosis. (Circulation.
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studies from our laboratory have demonstrated a significant linear correlation between increased neointimal growth and increased stent size relative to the proximal reference coro-nary artery lumen. 15 The objectives of the present study were to examine morphological predictors of in-stent restenosis in human coronary arteries focusing on arterial medial injury, neointimal inflammation, and underlying plaque morphology.
Methods
Stented human coronary arteries were accessioned at the Armed Forces Institute of Pathology for diagnostic consultation. Arteries were fixed in 10% neutral buffered formalin, radiographed, and processed for light microscopy. The length of the stented arterial segment was measured from postmortem radiographs. The stented arterial segment was placed intact into processing vials and dehydrated in a graded series of alcohols. Samples were then infiltrated with methylmethacrylate plastic and placed in airtight vials in a 38°C waterbath for polymerization. After polymerization, blocks were cut at 2-mm intervals along the entire length of the stents. Plastic sections (4 to 5 m thick) were then cut, adhered to glass slides, and allowed to dry. The plastic was then removed, and the sections were rehydrated and stained. In 28 cases, a 2-mm-long segment was cut from the midportion of the stented artery using fine scissors. The stent wires were carefully removed under a dissecting microscope before paraffin embedding. Plastic and paraffin sections were stained with hematoxylin and eosin and Movat pentachrome.
Selection of Cases
Coronary stents that had been implanted for Ն3 months were selected for analysis. In-stent restenosis was defined as a stent lumen cross-sectional area stenosis of Ͼ75% (equivalent to a stent lumen diameter stenosis of Ͼ50%). 16 No restenosis was defined as a stent lumen area stenosis of Յ75% (equivalent to a stent lumen diameter stenosis of Յ50%).
Morphological and Morphometry Measurements
The arterial segment from each stent demonstrating the greatest severity of in-stent stenosis was selected for analysis. Histological sections were magnified (ϫ20) and digitized, and computer-guided morphometry measurements were performed using IPLab Spectrum software (Scanalytics Inc). The following arterial measurements were made on each section: areas of internal elastic lamina, stent, underlying plaque, lipid core, calcific foci, lumen, and in-stent neointima. Stent area stenosis was calculated. Neointimal thickness was measured at each stent strut, and mean intimal thickness was calculated. The presence or absence of medial disruption was noted, and if present, the length of medial discontinuity (medial fracture length) was measured. Sections were additionally magnified (ϫ200), and 4 fields containing stent struts (12, 3, 6, and 9 o'clock) were selected for analysis of neointimal thickness, neointimal inflammatory cell density (cells/mm 2 ) around stent struts, and neointimal neoangiogenesis (area of endothelialized vascular channels [confirmed by von Willebrand factor staining] adjacent to stent struts). The stent strut was categorized as being associated with fibrous plaque (or an intact fibrous cap or intact media), medial injury, or lipid core penetration. Neointimal and plaque macrophages, T cells, B cells, and fibrin associated with stent struts were identified by immunohistochemistry (KP-1, UCHL, L26, and fibrin II stains, respectively) in paraffin sections.
Statistical Analysis
Numerical data are presented as meanϮSD. Continuous variables were compared using an ANOVA and simple linear regression. PՅ0.05 was considered significant.
Results

Patient Characteristics
The study group consisted of 56 individuals (36 men, 20 women, mean age 59Ϯ13 years) with coronary artery stents in place 10Ϯ7.1 months (range, 3 to 36 months) antemortem (25 patients Յ6 months duration of stenting; 31 patients, Ͼ6 months). The indications for stenting were unstable or postmyocardial infarction angina (nϭ23), stable angina (nϭ15), acute myocardial infarction (nϭ2), and unknown (nϭ16). Two patients underwent rotational atherectomy; no patients received brachytherapy. A total of 116 stents were placed in 87 coronary arteries, as follows: MULTI-LINK, nϭ53; AVE, nϭ28; Palmaz-Schatz, nϭ18; NIR, nϭ11; Gianturco-Roubin II, nϭ3; BardXT, nϭ2; and Gianturco-Roubin, nϭ1. Stent diameters ranged from 1.95 to 4.20 mm with 47 stents Ͻ3.0 mm in diameter, 23 stents 3.0 to 3.4 mm in diameter, and 17 stents Ն3.5 mm in diameter. The mean length of deployed stents was 22Ϯ14 mm (range, 8 to 73 mm). The arteries stented were as follows: left anterior descending, nϭ36; right coronary, nϭ26; left circumflex, nϭ17; left obtuse marginal, nϭ3; left diagonal, nϭ2; ramus intermedius, nϭ2; and left main, nϭ1. Patient mortality was attributable to sudden cardiac death (nϭ18), postcoronary revascularization (nϭ9), acute myocardial infarction (nϭ6), heart failure (nϭ4), and noncoronary death (nϭ19). Of the 87 stented arteries, in-stent restenosis was present in 42, and no restenosis was present in 45.
Morphometry
Final lumen area correlated with stent area (r 2 ϭ0.27, PϽ0.0001, Figure 1A ), but there was a much stronger correlation (r 2 ϭ0.70, PϽ0.0001) between stent area and neointimal area ( Figure 1B ). The lumen area was significantly smaller and the neointimal area was significantly greater in in-stent restenosis versus nonrestenosis cases (Table). The area within the internal elastic lamina (IEL) was slightly smaller in restenosis cases, but differences were not statistically significant. Plaque area as a function of IEL area, the percentage of plaque occupied by macrophages, and the areas of plaque calcification were similar in restenosis and no restenosis stents. The percentage of stent struts that were associated with fibrin deposits was greater in restenotic stents. The mean length of coronary stenting (1 to 4 stents per artery) was 24.5Ϯ14.9 mm in restenotic stents compared with 18.6Ϯ13.7 mm in nonrestenosis cases (Pϭ0.066). Stent areas were similar in stent restenosis and nonrestenosis cases.
Basic Morphometry: Long-Term Stent Patency Versus In-Stent Restenosis
Arterial Injury and Neointimal Growth
Medial fracture, present in 40 stented arteries and absent in 47 arteries, was associated with a 29% greater mean neointimal thickness (PϽ0.01) compared with stents without medial fracture ( Figure 2 , A through C). The mean stent area stenosis was 77Ϯ15% when medial fracture was present versus 68Ϯ20% when medial fracture was absent (PϽ0.04). Medial fracture length as a percent of the circumference of the internal elastic lamina was greater in restenotic stents (15.0Ϯ18.8%) compared with nonrestenotic cases (7.3Ϯ12.6%, PϽ0.03, Figure 2D ). In an analysis by stent struts, the neointima was thinner when stent struts were in contact with fibrous plaque, an intact fibrous cap, or normal media (0.68Ϯ0.36 mm) versus struts associated with arterial medial disruption (0.91Ϯ0.32 mm, Pϭ0.0001).
Inflammation and Neointimal Growth
The inflammatory infiltrates associated with stenting were composed predominately by macrophages with smaller numbers of T cells and rare B cells. Neointimal inflammatory cell density correlated with increased neointimal thickness (r 2 ϭ0.24, PϽ0.0001), and the mean number of inflammatory cells per four ϫ200 fields was 2.4-fold higher in restenosis versus no restenosis cases ( Figure 3A ). To gain insights into the effects of local morphology on neointimal inflammation, inflammatory cell accumulation around struts was measured as a function of the underlying arterial substrate (intact fibrous plaque, medial disruption, or lipid core penetration). Peri-strut inflammatory cell density was increased in regions of medial disruption (2259Ϯ2619 inflammatory cells/mm 2 ) compared with struts in contact with fibrous plaque or an intact fibrous cap (819Ϯ1094 inflammatory cells/mm 2 , PϽ0.0001, Figures 3B through 3D ). The percent of the neointima occupied by macrophages was 3-fold higher in restenosis versus no-restenosis cases ( Figure 4 ).
Neoangiogenesis, Intimal Growth, and Inflammation
Peri-strut neoangiogenesis area density correlated significantly but weakly with mean in-stent neointimal thickness (r 2 ϭ0.10, PϽ0.0001), and increased neoangiogenesis area density was associated with increased inflammatory cell density ( Figure 5 ). Struts associated with medial disruption had a greater vascular channels area density (0.010Ϯ 0.011 mm 2 /ϫ200 field) compared with struts in contact with fibrous plaque or an intact fibrous cap (0.004Ϯ0.006 mm 2 / ϫ200 field, PϽ0.0001, Figure 6 ).
Lipid Core Penetration by Stent Struts
Core penetration by stent struts was present in 16 cases. Lipid core penetration was associated with an increased neointimal thickness (0.88Ϯ0.50 mm, Pϭ0.04; Figure 7 , A and B) and increased numbers of peri-strut inflammatory cells (1493Ϯ2105 inflammatory cells/mm 2 , Pϭ0.03) compared with struts in contact with fibrous plaque (0.68Ϯ0.36 mm neointimal thickness and 819Ϯ1094 inflammatory cells/ mm 2 ). Neointimal vascular channel density was similar in cases of lipid core penetration versus struts in contact with fibrous plaque. Plaques with large lipid core areas and a greater percentage of the plaque occupied by a lipid core were more likely to be penetrated by stent struts; core area and the ratio of core area to plaque area in arteries with core penetration was 1.72Ϯ1.71 mm 2 and 37Ϯ44%, respectively, compared with 0.84Ϯ1.28 mm 2 and 14Ϯ18%, respectively, in arteries without core penetration (PϽ0.03, Figure 7E ).
Discussion
Angiographic factors associated with in-stent restenosis include small diameter reference coronary arteries, 5,6,17 longer lesion length, 4,5 and longer stent length. 5, 10 The present study adds important morphological data (extent of medial injury, inflammation, and neoangiogenesis) to the list of clinical and angiographic variables that are associated with outcome after coronary stenting. Notably, these local morphological parameters are not fully appreciated with present coronary artery imaging techniques.
Arterial Injury and Restenosis
Not unexpectedly, in-stent neointimal area correlated strongly (r 2 ϭ0.70) with increased stent size, because a larger-diameter deployed stent can accommodate a greater accumulation of neointimal tissue than a smaller stent. However, the much weaker correlation between stent size and lumen area (r 2 ϭ0.27) confirms that other factors besides stent size must be operative in determining long-term stent patency. In the present study, the potential benefit of "bigger is better" to reduce restenosis when applied to stenting is limited by increased arterial injury and inflammation. Clearly, medial injury and increased medial fracture length cause increased neointimal growth. Although damage to the arterial media is readily apparent by histology, arterial injury is difficult to quantify clinically. In present interventional cardiology practice, the operator cannot tightly control the degree of arterial injury (plaque disruption, medial stretch, medial dissection, or medial rupture) produced during catheter-based procedures. Intravascular ultrasound can recognize disruption in plaques (in the absence of calcification) but cannot precisely visualize the arterial media. The present study also underscores an important difference in human stenting compared with most experimental animal studies. In a normal animal artery, a properly sized (ie, nonoversized) stent is placed in apposition to the internal elastic lamina, causing mild arterial trauma. In humans, stents are expanded in a stenotic arterial segment to a diameter that matches a presumed normal reference segment; plaque disruption and arterial injury of varying degrees are unavoidable if lumen dilatation is to be achieved. The present study suggests that proper stent sizing and avoidance of excessive medial injury in the restoration of normal physiological blood flow are desirable goals in coronary stent placement rather than only maximizing lumen area.
Lipid Core Penetration and Restenosis
Fibrous cap rupture and stent strut penetration into the plaque lipid core were associated with increased neointimal growth. Plaques with large absolute lipid core size (Ն2.0 mm 2 ) and the percent of plaque occupied by the lipid core (Ն30% of total plaque area) identify lesions at increased risk for lipid core penetration by stent struts. These lipid-rich plaques may be predisposed to increased neointimal growth based on the presence of numerous resident chronic inflammatory cells associated with lipid cores. Stenting highly lipid-rich vulnerable lesions and disrupted plaques might be improved via the use of devices to aspirate large cores or through intensive lipid lowering or photodynamic therapy 18 to reduce plaque lipid and inflammatory cell content before stent deployment. Like medial injury, lipid core penetration by stents is associated with increased neointimal inflammation.
In contrast to intravascular ultrasound (IVUS), 19 we were unable to demonstrate a correlation between underlying plaque burden (plaque area/IEL area) and in-stent restenosis. We postulate that this difference reflects the more detailed analysis of arterial injury, inflammation, and neoangiogenesis afforded by histology that is beyond the resolution of IVUS. The present study does show that stent penetration into a plaque core, rather than just plaque size itself, is a determinant of increased neointimal growth. Lipid core penetration by stent struts (low power in A and high power in B) was associated with increased neointimal thickness (arrows) compared with stent struts in contact with fibrous plaque (C and D). Cholesterol clefts are indicated (arrowheads in B). Plaques with large lipid cores, occupying more than one third of the total plaque area, were at increased risk of lipid core penetration by the stent (E). A though D, Movat pentachrome stain. Scale barsϭ0.37 mm in A, 0.22 mm in B, 0.47 mm in C, and 0.20 in D.
Importance of Inflammation
Preclinical studies suggest that intimal inflammation is a determinant of in-stent neointimal growth. In stented rabbit iliac arteries, monocyte adhesion correlated with neointimal size (rϭ0.96). 14 A subsequent study showed peak monocyte adherence to the lumen surface 3 days after stenting, which correlated with intimal cellular proliferation (r 2 ϭ0.916). 20 In porcine coronary stents, lymphohistiocytic cell infiltration around stent struts was associated with increased intimal thickness and percent lumen area stenosis. 21 Furthermore, multiple studies demonstrate that treatments that inhibit inflammation and inflammatory cell adhesion molecules reduce intimal growth. In rabbit iliac artery stents, M1/70, a monoclonal antibody to the adhesion molecule Mac-1, reduced leukocyte recruitment Ͼ2-fold and reduced intimal area. 22 P-selectin knockout mice treated with carotid ligation had a 76% reduction in neointima/media area and reduced vessel wall leukocytes. 23 A monoclonal antibody against intercellular adhesion molecule-1 reduced the intima/media ratio by Ϸ50% in the rat carotid balloon injury model. 24 Inflammatory cells associated with coronary stent placement in humans have been previously described. 15 Neutrophils surrounding stent struts, typically observed early after stent placement, are absent beyond 30 days after deployment. In contrast, chronic inflammatory cells (macrophages and lymphocytes) are seen both early (3 to 7 days) and late (Ն6 months) after stenting. Furthermore, early after stenting (Յ3 days), the severity of inflammation in stented human coronary arteries is related to the underlying arterial wall morphology; stents in apposition to damaged arterial media or that penetrate the necrotic core of lipid-rich plaques are associated with greater numbers of inflammatory cells compared with struts in contact with fibrous plaque. 15 The present study extends these observations to intermediate-term to long-term stent implants. Arterial medial disruption and lipid core penetration by stent struts are both associated with chronic inflammation. These factors are in turn associated with greater neointimal growth. Because some degree of arterial injury is unavoidable during stenting, therapies directed against local inflammation are a logical target to reduce neointimal growth. Recent experimental and human studies have shown low in-stent restenosis rates with stents coated with rapamycin, an agent with both antiproliferative and antiinflammatory effects. 25, 26 
Significance of Neoangiogenesis
Neovessels, originating from the vasa vasorum, are commonly found in atherosclerotic plaques, and their growth is proportional to underlying plaque burden. 27 Intimal smooth muscle cells and macrophages express vascular endothelial growth factor (VEGF) in human atherosclerotic lesions. 28 Experimental studies have shown that arterial injury is associated with increased intimal and medial expression of VEGF, 29, 30 increased circulating VEGF, 31 and smooth muscle cell and endothelial cell proliferation in response to VEGF. 32 Neointimal vascularization within stents, noted previously by Brasen et al, 33 colocalizes with oxidative epitopes, iron deposits, VEGF, platelet-derived growth factor-BB, and microhemorrhages. We postulate that microvessel growth is stimulated by the release of VEGF by inflammatory cells. Chronic inflammation is augmented by the presence of a foreign body (stent) and arterial injury. It is possible that the constant motion of the semirigid stent damages peri-strut neovessels resulting in local hemorrhage and fibrin deposition. The presence of neovessels within the neointima offers a potential target for antirestenosis therapies. 34 
Limitations
As an autopsy study, the results presented may not be representative of persons who receive stents and survive without stent-associated morbidity. In the present study, however, a large number of stents were analyzed, most of which did not have histological in-stent restenosis.
Conclusion
Morphological studies of human coronary stent implants confirm the links among arterial injury, inflammation, and neointimal growth. Neoangiogenesis is associated with inflammation and may play a secondary role in restenosis. These data underscore the limitation of the "bigger is better" hypothesis when applied to stenting. Improved arterial imaging techniques may ultimately offer the interventional cardiologist the ability to optimally deploy stents with minimal arterial injury and avoidance of lipid core penetration. Reduction in stent-associated inflammation is a promising therapeutic target to improve late outcome.
